BioBlast® - Search
Chong Kun Dang and Menagen sign agreement for Nesbell® (biosimilar darbepoetin alfa)
Chong Kun Dang announced it has signed a commercialisation agreement with Menagen for Nesbell® (biosimilar darbepoetin alfa). Under the agreement, Chong Kun Dang will receive a down payment and milestone payments in exchange for exclusive commercialisation rights in Oman, Saudi Arabia, UAE, Kuwait Qatar and Bahrain.
JP | Dong-A ST receives sales approval for biosimilar darbepoetin in Japan
Dong-A ST announces sales approval for biosimilar darbepoetin from Japan’s Ministry of Health, Labour and Welfare.
TH |TW |VN | Lotus Pharma and Chong Kun Dang announce darbepoetin deal
Lotus Pharma announces it has signed a commercialisation agreement with Chong Kun Dang for Nesbell® (biosimilar darbepoetin-alpha). Under the agreement, Chong Kun Dang will supply Lotus with Nesbell® for sale in Taiwan, Vietnam and Thailand pending the success of clinical trials in those countries.
JCR announces results of Ph III darbepoetin trials
JCR announces results of Ph III trials of biosimilar darbepoetin candidate JR131 in patients with renal anemia. 159 patients enrolled in the 52 week study, with JCR reporting no adverse drug reactions, and that patient hemoglobin levels remained within the required 10.0 to 12.0 g/dL range throughout the study.
KR | Chong Kun Dang receives approval for biosimilar darbepoetin in South Korea
Chong Kun Dang announces approval for biosimilar darbepoetin from the Ministry of Food and Drug Safety of South Korea. This is the first biosimilar darbepoetin to be approved in a highly regulated country.
Kissei announces positive Ph III darbepoetin results
Kissei announces positive Ph III trials for JR131, biosimilar darbepoetin, with a view toward regulatory filing in 2018.
Product specific reports based on extracts from our BioBlast® database
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.